Melbourne, Australia and London, United Kingdom
Ori Biotech, Cell Therapies and AdAlta are joining forces to tackle cell therapy manufacturing challenges. We will work together to deploy Ori Biotech’s automated cell therapy manufacturing platform, IRO®, in Asia Pacific and across AdAlta’s cellular immunotherapy pipeline.
The collaboration supports AdAlta’s “East to West” strategy to deliver scalable, cost-effective cell therapies for solid cancers for global markets, and positions AdAlta and CTPL as leaders in advanced cell therapy manufacturing in Asia-Pacific.
To view the full announcement, click here: 2604121_Ori_CTPL_AdCella_MoU_ASX FINALV4
To see how IRO® works and join in with the conversation, go to AdAlta’s Investor Hub: https://investorhub.adalta.com.au/link/y05QZe
For further information please contact [email protected]
